


KU-57788

NU-7026


SCR7 pyrazine

**A**


A2780




A2780




A2780

**B**


IGROV-1




IGROV-1




IGROV-1

**C**


OVCAR-8




OVCAR-8




OVCAR-8

**D**


SK-OV-3





SK-OV-3





SK-OV-3





**Figure S1. Effect of NHEJi on OCCLs proliferation.** Cell proliferation after treatment with the indicated doses of KU-57788, NU-7026 or SCR7 pyrazine for 24, 48 and 72 h of (A) A2780, (B) IGROV-1, (C) OVCAR-8 and (D) SK-OV-3 cell lines.

**A****B**

**Figure S2. Effect of KU-57788 on cell cycle distribution in OCCLs.** Cell cycle distribution of live OCCLs (excluding the sub-G0 population) after treatment with the indicated doses of KU-57788 for 24, 48 and 72 h. Data are the mean of three independent experiments. Error bars represent the SD (\*\*p < 0.01, \*p < 0.05).





**Figure S3. Effect of NU-7026 on cell cycle distribution in OCCLs.** Cell cycle distribution of live OCCLs (excluding the sub-G0 population) after treatment with the indicated doses of NU-7026 for 24, 48 and 72 h. Data are the mean of three independent experiments. Error bars represent the SD (\*\*p < 0.01, \*p < 0.05). (B) Percentage of death cells after 24, 48 or 72 h of treatment with NU-7026.

**A****B**

**Figure S4. Effect of SCR7 pyrazine on cell cycle distribution in OCCLs.** (A) Cell cycle distribution of live OCCLs (excluding the sub-G0 population) after treatment with the indicated doses of SCR7 for 24, 48 and 72 h. Data are the mean of three independent experiments. Error bars represent the SD (\*\*p < 0.01, \*p < 0.05). (B) Percentage of death cells after 24, 48 or 72 h of treatment with SCR7.

### OVCAR-8

### A2780





Dose	D1	D2	D3	D1	D2	D3	D1	D2	D3	
CQ (µM)	-	20	30	40	-	-	-	20	30	40
NU (µM)	-	-	-	-	40	60	80	40	60	80
Survival (%)	96.6	90.9	91.0	77.0	88.0	80.9	59.9	83.0	58.7	30.8
Fa	0.03	0.09	0.09	0.23	0.12	0.19	0.40	0.17	0.41	0.69
CI	-	-	-	-	-	-	-	<b>1.34</b>	<b>1.04</b>	<b>0.76</b>

Dose	D1	D2	D3	D1	D2	D3	D1	D2	D3		
CQ (µM)	-	20	30	40	-	-	-	20	30	40	
NU (µM)	-	-	-	-	-	50	75	100	50	75	100
Survival (%)	93.4	90.9	84.0	76.8	85.2	81.0	59.8	77.7	60.8	38.8	
Fa	0.07	0.09	0.16	0.23	0.15	0.19	0.40	0.22	0.39	0.61	
CI	-	-	-	-	-	-	-	<b>1.03</b>	<b>0.88</b>	<b>0.66</b>	

### SK-OV-3

### IGROV-1




Dose	D1	D2	D3	D1	D2	D3	D1	D2	D3	
CQ (µM)	-	20	30	40	-	-	-	20	30	40
NU (µM)	-	-	-	-	20	30	40	20	30	40
Survival (%)	93.6	85.6	86.3	82.8	92.7	92.5	91.6	81.4	65.8	54.6
Fa	0.06	0.14	0.14	0.17	0.07	0.08	0.08	0.19	0.34	0.45
CI	-	-	-	-	-	-	-	<b>0.28</b>	<b>0.02</b>	<b>0.005</b>

Dose	D1	D2	D3	D1	D2	D3	D1	D2	D3		
CQ (µM)	-	20	30	40	-	-	-	20	30	40	
NU (µM)	-	-	-	-	-	20	30	40	20	30	40
Survival (%)	97.8	92.3	89.8	86.8	93.5	91.1	80.9	82.9	59.2	32.7	
Fa	0.02	0.08	0.10	0.13	0.07	0.09	0.19	0.17	0.41	0.67	
CI	-	-	-	-	-	-	-	<b>0.84</b>	<b>0.49</b>	<b>0.30</b>	


**Figure S5. Synergistic effect of chloroquine and NU-7026 in OCCLs.** Cells were exposed for 72 h to the indicated concentrations of NU and CQ at a constant ratio and the percentage of apoptotic cells were assessed by flow cytometry (after cell staining with annexin V and propidium iodide). CI values, calculated using Compusyn Software, are shown.

### OVCAR-8

### A2780




Dose	D1	D2	D3	D1	D2	D3	D1	D2	D3	
CQ (µM)	-	20	30	40	-	-	-	20	30	40
SCR7 (µM)	-	-	-	-	150	225	300	150	225	300
Survival (%)	90.0	84.4	79.4	66.5	69.8	44.2	54.4	26.2	21.7	7.8
Fa	0.10	0.16	0.21	0.34	0.30	0.56	0.46	0.74	0.78	0.92
CI	-	-	-	-	-	-	-	0.34	0.42	0.21



Dose	D1	D2	D3	D1	D2	D3	D1	D2	D3	
CQ (µM)	-	20	30	40	-	-	-	20	30	40
SCR7 (µM)	-	-	-	-	100	150	200	100	150	200
Survival (%)	97.2	92.5	91.5	88.1	97.4	97.0	97.1	93.1	84.6	63.3
Fa	0.03	0.08	0.09	0.12	0.03	0.03	0.03	0.07	0.15	0.37
CI	-	-	-	-	-	-	-	1.07	0.45	0.12

### SK-OV-3


### IGROV-1



Dose	D1	D2	D3	D1	D2	D3	D1	D2	D3	
CQ (µM)	-	20	30	40	-	-	-	20	30	40
SCR7 (µM)	-	-	-	-	125	187.5	250	125	187.5	250
Survival (%)	94.5	87.9	81.7	83.3	93.4	91.1	91.0	89.1	64.4	67.8
Fa	0.06	0.12	0.18	0.17	0.07	0.09	0.09	0.11	0.36	0.32
CI	-	-	-	-	-	-	-	1.75	0.19	0.32

Dose	D1	D2	D3	D1	D2	D3	D1	D2	D3	
CQ (µM)	-	20	30	40	-	-	-	20	30	40
SCR7 (µM)	-	-	-	-	100	150	200	100	150	200
Survival (%)	97.1	90.9	87.6	84.2	96.3	95.9	95.3	84.1	85.8	75.2
Fa	0.03	0.09	0.12	0.16	0.04	0.04	0.05	0.16	0.14	0.25
CI	-	-	-	-	-	-	-	0.50	0.88	0.54

**Figure S6. Synergistic effect of chloroquine and SCR7 pyrazine in OCCLs.** Cells were exposed for 72 h to the indicated concentrations of SCR7 and CQ at a constant ratio and the percentage of apoptotic cells were assessed by flow cytometry (after cell staining with annexin V and propidium iodide). CI values, calculated using CompuSyn Software, are shown.



**Figure S7. Clonogenic assays.** A2780 cells were seeded in 6 well plates and 24 h later they were incubated in the presence of the indicated compounds for 72 hours. Cells were then washed with PBS and incubated in complete RPMI1640 medium for 5 days. Colonies were fixed with 4% paraformaldehyde and stained with crystal violet.